Evercore ISI upgraded CRISPR Therapeutics to Outperform due to upcoming catalysts like CTX320 and CTX310 in vivo programs. They predict data for CTX320 in Q2 and CTX310 later this year.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay
CRISPR (CRSP) Upgraded to Outperform by Evercore, Price Target Raised to $99
